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The objective of this study was to identify differences in disposition and esterase 
hydrolysis of ramipril between male and female volunteers. Plasma concentration and 
area under the concentration-time curve until the last measured concentration (AUCt) 
data of ramipril and its active metabolite ramiprilat (-diacid) were obtained from a 
randomised, cross-over bioequivalence study in 36 subjects (18 females and 18 males). 
Participants received a single 5-mg oral dose of two different formulations of ramipril 
(Formulation I and II). Plasma ramipril and ramiprilat concentrations were determined 
according to validated methods involving liquid chromatography-mass spectrometry.  
A total number of 2 × 34 available plasma concentration-time curves of both the 
parent drug and the metabolite could be analysed, and variations (50–100% coefficient of 
variation [CV]) in plasma concentrations of both parent drug and metabolite were found. 
With both the formulations, the mean plasma concentrations-time curves of males and 
females were identical. The groups of female and male volunteers showed similar yields 
(AUCt = µg.h/L) of the metabolite ramiprilat (p = 0.37); however, females showed a higher 
AUCt/kg than males (p = 0.046). This difference was solely attributed to the difference in 
body weight between males and females (p = 0.00049). In both male and female groups, a 
subject-dependent yield of active metabolite ramiprilat was demonstrated, which was 
independent of the formulation. 
There is a large variation in the ramiprilat t1/2β (50–60% CV). There is a group of 
subjects who showed a t1/2β of approximately 80 h (15% CV), and two apparent groups 
with a longer t1/2β for each formulation (124 h, 22.5% CV; 166 h, 21.6% CV, respectively, p 
= 0.0013). This variation in the terminal half-life of ramiprilat is not sex related. In all three 
groups of half-lives, the corresponding Cmax values (mean ± SD) of ramiprilat in males 
and females were identical. Thus, with identical Cmax and half-lives, the difference found 
in the AUCt/kg of ramiprilat must be due to the difference in dose, as the consequence of 
the difference in body weight, following a standard dose of 5 mg in both males and 
females. 
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Netherlands. Tel: +31-24-361-5363, Fax +31-24-354-0462 
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This study showed clearly that despite subject-dependent hydrolysis of ramipril to 
the active metabolite ramiprilat, the variability in the rate of hydrolysis between males 
and females is similar. With a fixed dose (5 mg), females received a higher dose/kg than 
males and consequently showed a higher AUCt/kg of the active metabolite ramiprilat.  
KEYWORDS: ramipril, ramiprilat, pharmacokinetics, liver, gut, hydrolysis, plasma concentration, 
male-female, elimination half-life 
DOMAINS: pharmaceutical sciences 
 
INTRODUCTION 
RAMIPRIL is a member of the second generation of angiotensin-converting enzyme (ACE) 
inhibitors[1,2,3]. It is a pro-drug that is hydrolysed in vivo releasing the active metabolite ramiprilat[4,5]. 
The metabolite has a long elimination half-life (≈100 h) permitting once-a-day administration[1,2]. 
Ramiprilat binds to ACE with very high affinity, and is active at concentrations similar to those of the 
enzyme, establishing the equilibrium slowly[6]. 
The clinical data confirm ramipril as a useful ACE-inhibitor alternative for the treatment of patients 
with mild to moderate hypertension, with an indication of the beneficial effect in patients with clinical 
evidence of heart failure after acute myocardial infarction. Ramipril is also supposed to be valuable in the 
treatment of patients with more established heart failure of asymptomatic left ventricular dysfunction. 
When administered to patients with essential hypertension, a single oral dose of 2.5–10 mg decreased 
systolic and diastolic blood pressure in a dose-dependent manner without affecting the normal circadian 
variation in blood pressure or heart rate[2].  
Following administration of 5 mg of ramipril, the maximum inhibition of ACE activity in plasma of 
98.2 ± 2.18% was observed after 2.74 ± 1.42 h (mean ± SD). The relationship between the concentrations 
of ramiprilat and the inhibition of ACE activity subsequently declined in an exponential manner. The 
duration of inhibition >80% of plasma ACE activity was 16.8 ± 4.47 h. The half-maximum effect 
occurred at a plasma concentration of about 1 ng/mL of ramiprilat; at a concentration of 2 ng/mL, ACE 
activity was inhibited by more than 80%[7,8]. Enzyme activity was still inhibited by 40–50% at 72 h after 
the dose of ramipril[8,9]. In the treatment of mild to moderate essential hypertension, the initial 
recommended oral dose of ramipril is normally 2.5 mg once daily. The dosage should be titrated 
according to the patient’s blood pressure response, and the usual maintenance dosage is 2.5 or 5 mg/d, 
with a maximum daily dose of 10 mg[3,10].  
A bioequivalence study with 36 subjects (males/females) and a dose of 5 mg ramipril revealed 
subject-related differences in the absorption, metabolism, and elimination of ramipril and its primary 
active metabolite, ramiprilat. The fixed dose for each subject resulted in different doses when expressed 
as dosage/body weight.  
The aim of this study was to investigate whether the parameters of sex and body weight cause great 
variation in the part of the ramipril dose that is hydrolysed by esterase activity, using the plasma 
concentration-time curves of ramipril and its primary active metabolite.  
 
METHODS 
 
Experimental Design 
The evaluation was based on the data of plasma concentration-time curves obtained from a single centre, 
open, randomised, two-way, crossover bioequivalence study on ramipril 5-mg tablet (Biochemie GmbH, 
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Kundl, Austria) vs. Delix® 5 mg (Hoechst AG, Haar, Germany) involving 36 healthy Caucasian 
volunteers without any comedication. 
The clinical trial was conducted by Cepha s.r.o. (Pilsen, Czech Republic) after being granted approval 
by the Institutional Ethics Board and after informed consent was obtained from the subjects. 
Subjects 
Thirty-six healthy Caucasian subjects (from the Charles University, Medical School, Pilsen), 18 males 
and 18 females (nonpregnant, nonbreastfeeding) participated in the study. The demographic data are 
summarised in Table 1. 
Inclusion Criteria 
Age: 18–45 years, body-mass index 19–28 kg/m2, physical examination without significant deviations, 
vital signs and ECG without significant deviations, all laboratory screening results within the normal 
range or being assessed as nonsignificant by the attending physician. 
Exclusion Criteria 
• History of severe allergy or allergic reactions to study or related drug 
• History of serious clinical illness that can impact fate of drugs 
• Clinically significant illness within 4 weeks before study period 1 
• Any significant clinical abnormality including HBsAg, HIV positivity 
• Sitting blood pressure after 5 min rest lower than 100/50 mmHg 
• Pregnancy, breastfeeding 
• Serious mental disease, drug, alcohol, solvents or caffeine abuse, smoking more than ten 
cigarettes per day 
• Regular use of medication except oral contraceptive steroids (OCS) taken without changes for 3 
months at least 
• Use of organ toxic drugs within 3 months before study period 1 
• Systemic treatment by drugs (1) inducing hepatic metabolism, (2) similar to the investigational 
drug within 30 d before study period 1 
• Any systemic prescription drug treatment within 14 d before study period 1 
• Any systemic over-the-counter (OTC) drug treatment within 7 d before study period 1 
• Donation of (1) at least 400 mL of blood within 60 d, (2) more than 150 mL of blood within 30 d, 
or (3) blood plasma or platelets within 14 d before study period 1 
• Participation in another clinical trial within 60 d prior to the start of study period 1  
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TABLE 1 
Comparison Between the Pharmacokinetic Parameters of Ramipril and Ramiprilat (Formulation I + 
II) in Males and Females 
 Males Females p All 
Dose, 5 mg     
N 2 × 16 2 × 18   
Age, year 26.8 ± 5.9 26.9 ± 8.3 0.99  
Height, cm 180 ± 6.9 169 ± 4.4 <0.0001  
Body weight, kg 79.5 ± 11.8 65.7 ± 7.7 0.00049  
Dose, µg/kg 64.4 ± 10.6 77.1 ± 8.7 0.00047  
Ramipril     
AUCt, µg.h/L 10.3 ± 7.76 10.5 ± 6.37 0.91 10.4 ± 7.09 
AUCt/kg, µg.h/L/kg 0.131 ± 0.093 0.157 ± 0.009 0.10 0.143 ± 0.009 
t1/2 abs, h 0.08 ± 0.12 0.07 ± 0.07 0.67 0.08 ± 0.09 
t1/2α, h 0.26 ± 0.17 0.20 ± 0.08 0.06 0.23 ± 0.14 
t1/2β, h 1.27 ± 0.75 1.32 ± 1.13 0.83 1.30 ± 1.94 
MRT, h 1.24 ± 0.49 1.11 ± 0.55 0.31 1.18 ± 0.52 
tlag, h 0.16 ± 0.02 0.16 ± 0.02 1.00 0.16 ± 0.02 
tmax,, h 0.34 ± 0.17 0.30 ± 0.06 0.19 0.32 ± 0.13 
Cmax, µg/L 12.7 ± 5.90 16.0 ± 6.19 0.028 14.3 ± 6.20 
Ramiprilat     
AUCt, µg.h/L 137 ± 33.8 130 ± 28.3 0.37 134 ± 31.0 
AUCt/kg, µg.h/L/kg 1.75 ± 0.44 1.97 ± 0.45 0.046 1.85 ± 0.45 
t1/2 abs, h 2.06 ± 0.76 2.42 ± 0.96 0.09 2.24 ± 0.86 
t1/2α, h 2.69 ± 2.18 2.93 ± 1.26 0.58 2.80 ± 1.78 
t1/2β, h 118 ± 66.1 104 ± 33.5 0.97 111 ± 53.2 
MRT, h 158 ± 94.0 133 ± 42.4 0.16 145 ± 74.5 
tlag h 0.13 ± 0.16 0.10 ± 0.03 0.27 0.11 ± 0.11 
tmax, h 4.25 ± 1.45 4.61 ± 1.69 0.35 4.33 ± 1.54 
Cmax, µg/L 4.14 ± 1.67 4.29 ± 1.50 0.70 4.18 ± 1.57 
Trial Course 
Participants were divided randomly into two groups with the aid of a computer-generated randomisation 
list. Group 1 was assigned to treatment sequence I-II (Formulation I and II). Group 2 was assigned to 
sequence II-I. During the cross-over sessions, volunteers received each of the following treatments after 
an overnight fast, administered with 240 mL of water: 
• Formulation I: single oral dose of one ramipril 5-mg tablet, batch number 276 (Ramipril, 
Biochemie GmbH, Kundl, Austria)  
• Formulation II: single oral dose of one ramipril 5-mg tablet, batch number 40C503 (Delix®, 
Hoechst, Germany) 
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Drugs 
• Ramipril (C23H32N2O5, MW 416.22, [2S-[1[R*(R*)], 2α, 3aβ, 6aβ]]-1-[2 [[1-
(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta [b]pyrrole–2-
carboxylic acid, CAS - 87333-19-5 and 
• Ramiprilat C21H28N2O5, MW 388.52, [2S-[1[R*(R*)], 2α, 3aβ, 6aβ]]-1-[2 [[1-(carbonyl)-3-
phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, were 
obtained from Biochemie. 
Drug Administration 
Before drug administration, participants fasted for at least 10 h, and this was continued until 4 h after drug 
administration. The subjects were not allowed to lie down or sleep for the first 3 h after dosing, to ensure 
normal absorption. If dizziness occurred, the subjects were permitted to lie down on their right side. 
No alcohol-, caffeine-, xanthine- or grapefruit-containing food or drink was allowed within 72 h 
before each drug administration and during the confinement postdose periods.
From 48 h prior to each study period until 32 h after each study period, the intake of CO2-containing 
beverages and smoking were prohibited. No strenuous activities were allowed 24 h before screening and 
follow-up examinations. 
Food and Fluid Intake 
The subjects received 240 mL of water upon drug administration, and at 2 and 5 h after drug 
administration. Standardised meals with additional fluid (240 mL) were provided 10.5 h before drug 
administration and at 5 h (with 490 mL fluid), 9 h (with 240 mL), 12 h (with 240 mL), 15 h (with 240 
mL), 25 h (with 240 mL), and 29 h (with 490 mL) after drug administration. The subjects were free to 
drink additional supplied beverages free of alcohol, CO2, caffeine, and grapefruit from 6 h after drug 
administration. 
Blood Sampling 
On the day of drug administration, an indwelling intravenous cannula (Vasocan Braunüle 20 G 11/4") 
was inserted in a forearm vein of each volunteer. The cannula was removed after withdrawal of the 16-h 
postadministration sample. The remaining blood samples (24–96 h) were drawn by venepuncture. 
Blood samples (8 mL) were collected in polypropylene test tubes, containing 0.20 mL of 5% 
Na2EDTA as anticoagulant, just before administration and at 0.17, 0.50, 0.75, 1, 1.33, 1.67, 2, 3, 4, 5, 6, 
8, 10, 12, 16, 24, 32, 48, 72, and 96 h after administration. 
The blood samples were shaken gently, and centrifuged within 15 min of collection at 4000 rpm 
(2000 g) for 10 min at 4oC. The plasma samples were collected in three splits, capped, flash frozen and 
kept on dry ice until their storage in the freezer at –25 ± 5oC. The frozen plasma samples were stored in a 
freezer with CO2 back-up at –25 ± 5oC until their transportation on dry ice to the bioanalytical facility of 
Quinta-analytica and stored thereafter at –25 ± 5oC until analysis. 
Bioanalysis 
Ramipril and its metabolite ramiprilat were analysed by means of high performance liquid 
chromatography-mass spectrometry (LC-MS, Quinta-analytica s.r.o., Prague, Czech Republic).  
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In brief: 
Chemicals 
• Ramipril C23H32N2O5, MW 416.52; Ramiprilat C21H28N2O5, MW 388.47 
Internal standards 
• Enalapril C20H28N2O5, MW 376.45 (Maleate salt, batch no 038H0500, Sigma) 
• Enalaprilat C18H24N2O5, MW 348.40 (Quinta-Analytica) 
• Chemicals (pro-analysis) were obtained from Baker, Merck, Fluka, Sigma, and Novartis. 
Instrumentation 
RHEOS 2000 (Flux Instrument) HPLC, with a MS detector (TSQ, ThermoQuest/Finnigan), equipped 
with a column: TPR-100, 5 µm (3.0 × 20 mm, Supelco). Injection: 15 µL. Acquisition; ESI mode, 
positive polarity, scan MS/MS. 
Mobile phase: acetonitrile, methanol, 2% formic acid, and water, in a program mode during 4.5 min, 
and a flow rate varying between 350 and 1200 µL/min. 
The mass-chromatograms reconstructed from the ion profiles corresponding to ramipril (m/z 233.5), 
ramiprilat (m/z 205.5), enalapril (m/z 233.5) and enalaprilat (m/z 205.5) have been integrated and the 
ratios ramipril/enalapril and ramiprilat/enalaprilat were used for the calculation of the concentrations of 
ramipril and ramiprilat. Retention time of the analytes was 1.1 min.  
Sample Treatment  
0.05 mL of internal standard solutions (10 µg/mL enalapril and enalaprilat), 0.05 mL of water, or 0.05 mL 
of the appropriate working solutions of ramipril and ramiprilat, 1.0 mL of drug free plasma and 0.15 mL 
of 10% formic acid in water were pipetted into test tubes. Blank samples were without working and 
internal standard solutions. All samples were homogenised by vortexing for 5 s, and put into a freezer (–
25oC) for further processing.  
Before processing, the samples were thawed. After centrifugation, the samples were transferred onto 
extraction columns and the analytes were isolated from plasma by a solid-phase extraction procedure. 
After extraction the samples were evaporated to dryness, the residues were dissolved in 0.2 mL of 25% 
acetonitrile with 5% formic acid and then analysed using a HPLC/MS system. 
Performance 
Ramipril 
The linear response was observed in the ramipril/enalapril peak area ratio over the concentration range 
0.2–40 ng/mL (r = 0.999). The Lower Limit of Quantification (LOQ) was 0.2 ng/mL (3.1% CV) at a 
signal to noise ratio of 5.  
The intra-assay precision was 3.4% with the accuracy –0.7%, at a concentration of 0.20 ± 0.007 
ng/mL. These data were 3.9% precision and –1.8% accuracy at 39.3 ± 1.54 ng/mL. 
The inter-assay precision was 3.4% with the accuracy –0.7%, at a concentration of 0.20 ± 0.007 
ng/mL. These data were 1.1% precision and –1.8% accuracy at 40.2 ± 0.43 ng/mL. 
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Ramiprilat 
The linear response was observed in the ramiprilat/enalaprilat peak area ratio over the concentration range 
0.2–20 ng/mL (r = 0.999). The Lower Limit of Quantification (LOQ) was 0.2 ng/mL (3.1% CV) at a 
signal to noise ratio of 5.  
The intra-assay precision was 7.4% with the accuracy –4.4%, at a concentration of 0.19 ± 0.014 
ng/mL. These data were 2.7% precision and –1.6% accuracy at 19.7 ± 0.54 ng/mL. 
The inter-assay precision was 7.4% with the accuracy –4.4%, at a concentration of 0.20 ± 0.007 
ng/mL. These data were 1.8% precision and –0.5% accuracy at 19.9 ± 0.35 ng/mL. 
Pharmacokinetic Analysis 
Based on plasma ramipril and ramiprilat concentrations of individual volunteers, the following 
pharmacokinetic parameters were determined by noncompartmental and two-compartmental analysis 
using the program MW/Pharm[11]. 
• Maximum plasma concentration (Cmax, µg/L); time to reach peak concentration (tmax, h)  
• Area under the plasma concentration-time curve until the time of the last measured concentration 
(Ct), calculated by the linear trapezoidal rule (AUCt, µg.h/L) 
• AUCt/kg is the AUCt corrected for the body weight 
• Elimination half-life (t1/2β) associated with the terminal slope of a semilogarithmic concentration-
time curve (t1/2z, h) calculated as ln2/λz, where λz is the elimination rate constant 
• Lag time (tlag) was defined as the time between administration and first measurable plasma 
concentration 
• t1/2absorption was the absorption half-life 
• t1/2α was the half-life of the rapid elimination phase  
• Mean residence time (MRT) = AUCM0–∞/AUC0–∞, where AUC0-∞ was the area under the moment 
curve from zero to infinity 
Statistical Analysis 
Analysis of variance (ANOVA, two-tailed, Gaussian distribution) of the pharmacokinetic parameters was 
carried out and significance was defined at p < 0.05.  
RESULTS 
A total number of 2 × 34 available plasma concentration-time curves of both the parent drug and the 
metabolite were analysed, and variations (50–100% CV) in plasma concentrations of both parent drug and 
metabolite were found. With both the formulations, the mean plasma concentrations-time curves of males 
and females were identical. 
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FIGURE 1. Mean plasma concentration-time curves of ramipril (open markers) and its metabolite, ramiprilat (solid markers), in 16 males (M, 
dots) and 18 females (F, squares) after the oral administration of 5 mg ramipril (Formulation I). Males and females show identical mean plasma 
concentration curves. Similar results were obtained when after administration of Formulation II. SD bars are omitted for reasons of clarity. The 
50% ACE activity is present at 1 ng/mL (1 µg/L).  
The exemplary mean plasma concentration-time curves of males and females with Formulation I are 
given in Fig. 1.  
The pharmacokinetic parameters of ramipril and ramiprilat in males and females are shown in Table 1 
after administration of Formulation I + II. The demographic parameters body weight, and body length 
show statistical significant differences between males and females. The pharmacokinetic parameters of 
ramipril and ramiprilat in males and females were identical. 
Ramipril pharmacokinetics — ramipril is rapidly absorbed from the gastrointestinal tract, as shown 
by the small lag-time of 0.16 ± 0.02 h, a small t1/2absorption of 0.08 ± 0.09 h, the small tmax of 0.32 ± 0.13 h, 
and the Cmax of 14.3 ± 6.2 mg/L (all subjects). After absorption. ramipril was eliminated following a two 
compartment-model (r = 0.999) with a t1/2α of 0.23 ± 0.14 h and a t1/2β of 1.30 ± 1.94 h. A perfect two-
compartment elimination kinetics after oral administration was obtained in the individual curves when the 
ratio t1/2absorption:t1/2α:t1/2β is 1:5:25. This ratio was present in 53 administrations, but was 1:1:5 in 15 
administrations (7M, 8F). 
Ramiprilat pharmacokinetics — ramiprilat is rapidly formed from the gastrointestinal tract, as 
shown by the small lag-time of 0.11 ± 0.11 h, a small t1/2absorption of 2.24 ± 0.81 h, the tmax of 4.33 ± 1.54 h, 
and the Cmax of 4.18 ± 1.57 mg/L (all subjects). After formation, ramiprilat was eliminated following a 
two compartment-model (r = 0.999) with a t1/2α of 2.80 ± 1.78 h and a t1/2β of 111 ± 53.2 h. A perfect two-
compartment elimination kinetics after oral administration was obtained in the individual curves when the 
ratio t1/2absorption:t1/2α:t1/2β is 1:1:50. This ratio was present in 54 administrations (26F, 28M), but was 
0.1:5:50 in 14 administrations (6M, 8F).  
The deviation from the ideal ratio of the rate constants in the majority of the subjects in ramipril and 
ramiprilat was not related to the subjects, only 4 subjects (3M, 1F) (13.8%, out of 15 ramipril and 14 
ramiprilat ratio deviations) showed deviations in both compounds.  
It seems that Cmax and t1/2 values are independent parameters, the sex ratio is evenly spread over the 
groups based on these two parameters. 
There is a large variation in the t1/2β (50–60% CV). There is a group of subjects who showed a t1/2β of 
approximately 80 h (15% CV), and an apparent second group with a longer t1/2β for each formulation (124 
h, 22.5% CV; 166 h, 21.6% CV) as shown in Table 2. 
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TABLE 2 
Variation in the Terminal Elimination Half-Life (h) of Ramiprilat in  
Apparent Groups of Subjects (34 Subjects) 
Formulation I n II n p 
All 103 ± 67 h (34) 120 ± 68 h (34) 0.29 
Subgroup a 78 ± 12 h (18) 81 ± 11 h (18) 0.42 
p <0.0001  <0.0001   
Subgroup b 124 ± 28 h (16) 166 ± 36 h (16) 0.0013 
The terminal half-lives (h) do not depend on the male/female sex difference. 
Subgroup a      
Males 78.4 ± 11.9 (9) 77.8 ± 21.0 (8)  
p 0.63  0.71   
Females 81.4 ± 13.2 (9) 80.7 ± 11.1 (10)  
Subgroup b      
Males 120 ± 23.0 (8) 142 ± 21.4 (7)  
p 0.60  0.28   
Females 128 ± 32.5 (8) 188 ± 37.3 (9)  
Table 2 shows that the variation in the terminal half-life of ramiprilat is not sex related. Also, in all 
groups of half-lives, the corresponding Cmax values (mean ± SD) of ramiprilat in males and females were 
identical. 
Thus, with identical Cmax and half-lives, the difference found in the AUCt/kg of ramiprilat (Fig. 3) 
must be due to the difference in dose, as the consequence of the difference in body weight, following a 
standard dose of 5 mg in both males and females. 
Male-Female Differences in Ramipril Hydrolysis 
Exemplary differences in AUCt of both ramipril and the active metabolite ramiprilat for males and 
females of Formulation II are shown in Fig. 2. In this small group of subjects no difference was found 
between males and females (p = 0.93). 
When the AUCt/kg of both ramipril and the active metabolite ramiprilat for males and females of all 
data (Formulation I + II) were plotted, as shown in Fig. 3, females showed a significant higher AUCt/kg 
for ramiprilat than males (p = 0.046), while the corresponding data for ramipril were similar (p = 0.26).  
Intersubject Variation of Ramipril Hydrolysis  
A scatter plot of datapoints of Formulation I + II is obtained when the AUCt/body weight of ramipril is 
plotted vs. that of the metabolite in females shown in Fig. 4 and in males shown in Fig. 5. There is a 
tenfold variation in the ramipril data, and a threefold variation in the ramiprilat data, indicating a more or 
less constant variation in hydrolysis.  
The AUCt/kg data of ramiprilat are a factor 10 higher than those of the parent drug ramipril. 
In Fig. 4, female subject 1 appeared to be a slow hydrolyser, all other subjects hydrolyse ramipril in a 
comparable manner. The whole group can be split into two apparent subgroups, with similar slopes of the 
regression lines (p = 0.51), but with different Y-intercepts (p < 0.0001).  
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FIGURE 2. AUCt ramipril plotted vs. the AUCt of the metabolite ramiprilat after the oral administration of 5 mg ramipril (Formulation II) to 
male and female subjects. There is a 7-fold variation in the AUCt ramipril, with a 1.5-fold variation in the AUCt of the metabolite. No difference 
between males (solid dots) and females (open dots) in the hydrolysis of ramipril Formulation II (p = 0.93). Similar results were obtained for 
Formulation I (p = 0.93). The hydrolysis of ramipril in ramiprilat must be instantaneous, or by the gastrointestinal tract, because when 
extrapolating to t = 0 (lim X → 0), there is a substantial amount of ramiprilat present with no measurable AUCt of the parent drug.  
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FIGURE 3. AUCt/kg ramipril plotted vs. the AUCt /kg of the metabolite ramiprilat after the oral administration of 5 mg ramipril (Formulation I + 
II). There is a difference between males (solid dot, n = 32) and females (open dot, n = 36) in the hydrolysis of ramipril (p = 0.046).  
In Fig. 5, two male subjects (#2 and #27), appeared to be slow hydrolysers, all other subjects 
hydrolyse ramipril in a comparable manner. The whole group can be split into two apparent subgroups, 
with different slopes of the regression lines (p < 0.0001), and with different Y-intercepts (p = 0.0002).  
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FIGURE 4. AUCt/kg ramipril plotted vs. the AUCt /kg of the metabolite ramiprilat after the oral administration of 5 mg ramipril (Formulation I + 
II in females). Two apparent subgroups can be distinguished, each with a similar slope of the regression line (p = 0.51) but with different Y-
intercepts (p < 0.0001). Subject 1 hydrolyses ramipril very slowly (F = first administration and f = second administration).  
0 0.10 0.20 0.30 0.40 0.50 0.60
AUCt Ramipril  ug.h/L/kg
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
A
U
C t
 R
am
ip
ril
at
  u
g.
h/
L/
kg
Ramipril hydrolysis
Males
Formulation I+II
2m
2M
27m
27M
A
B
C
A  y=9.44x + 1.31  r=0.47
B  y=5.20x + 0.86  r=0.78
C  y=1.81x + 0.50  r=0.81
 
FIGURE 5. AUCt/kg ramipril plotted vs. the AUCt /kg of the metabolite ramiprilat after the oral administration of 5 mg ramipril (Formulation I + 
II in males). Two apparent subgroups can be distinguished, each with a different slope of the regression line (p < 0.0001) and with different Y-
intercepts (p = 0.0002). Subjects 2 and 27 hydrolyse ramipril very slowly (M first administration, m second administration).  
There is no male-female difference between the two highest groups of Figs. 4 and 5, concerning the 
slopes (p = 0.061) and the Y-intercepts (p = 0.85). The difference is present in the lowest group, slope (F 
> M, p < 0.0001) and Y-intercept (M > F, p < 0.0001). 
 
 
 1354
Vree et al.: Male-Female Differences TheScientificWorldJOURNAL (2003) 3, 1344–1358 
 
Discrimination between Hydrolysis of Ramipril by the Gastrointestinal Tract and 
by the Plasma/Liver 
When plasma and hepatic esterase hydrolysis of ramipril takes place, then the parent drug first must be 
absorbed and then hydrolysed. This means that with AUCparent approaching zero (lim X → 0), the resulting 
corresponding AUCmetabolite also must approach zero (lim Y → 0). 
In the AUCt ramipril vs. AUCt ramiprilat plot of Formulation I + II in Figs. 4 and 5, two apparent 
subgroups of subjects could be distinguished in the groups of males and females, each of which has a 
specific yield (AUCt) of the metabolite ramiprilat.  
There is a group of 33 administrations (15M, 18F) that renders the highest AUCt of metabolite, a 
group of 29 administrations (13M, 16F) that renders a low AUCt, and a group of 6 administrations (4M, 
2F) with the lowest AUCt (n = 68). The 95% confidence interval (CI) of the Y-intercept of the subjects 
who have the high and low of hydrolysis both does not contain the origin of the axis, indicating tissue 
hydrolysis with additional hydrolysis by liver and plasma. The 95% CI interval of the lowest hydrolysers 
contains the origin, indicating mainly tissue hydrolysis (low slope, low Y-intercept). 
DISCUSSION 
In this study we investigated the plasma concentration-time curves and the pharmacokinetics of ramipril 
and its active metabolite, ramiprilat. The pharmacokinetic parameters found correspond well with those 
reported earlier[12,13,14]. 
Ramipril undergoes extensive first-pass metabolism and therefore only small amounts of unchanged 
ramipril can be found in urine and bile[8,15]. Both ramipril and ramiprilat are conjugated to the respective 
glucuronides, and the corresponding diketopiperazine derivatives are also formed[13,14,15,16]. Renal 
excretion is the main route of elimination of the parent drug and ramiprilat with their respective metabolites. 
Approximately 60% of a single oral dose of ramipril is recovered in the urine, while the remaining 40% is 
recovered in the faeces and includes biliary excretion, with significant enterohepatic circulation occurring 
in the dog, and presumably also in humans[2,7,13,17,18,19,20].  
The remarkable difference between the terminal half-lives of ramiprilat in subgroups of the volunteers 
(80 h vs. 124–166 h) may raise the question why 50% of the subjects show this relatively “fast” 
elimination of 80 h and the other 50% a wide variety in extreme long half-lives. If there is no 
enterohepatic recirculation of ramiprilat glucuronide, the half-life of 80 h may represent the dissociation 
kinetics of the ACE-ramiprilat complex[21]. Interindividual variation in the enterohepatic recirculation of 
ramiprilat glucuronide may add to this interindividual (independent of sex) variation in the terminal half-
life[22]. 
Another possibility may be that the variation in polymorph ACE-genes and variation in subsequent 
binding constants may play a role in the terminal half-life variation[23].  
This study revealed a subject-dependent rate of formation of the active metabolite ramiprilat, in both 
females and males, which was independent of the formulation. Females showed a higher AUCt/kg of 
ramiprilat than males, due to the higher dose/kg. The AUCt values of ramiprilat of both females and males 
were similar, due to the big variation in the long terminal half-life. As shown earlier for the acetylation of 
mesalazine and the hydrolysis of simvastatin and lovastatin by the liver and by the gastrointestinal tract, it 
was possible to discriminate between hydrolysis of ramipril by plasma/hepatic or tissue esterase 
activity[24,25,26]. When only plasma/liver esterase activity is responsible for the hydrolysis of ramipril, 
with the AUCt/kg for ramipril approaching zero (lim X → 0), the AUCt/kg for the metabolite must also 
approach zero (lim Y → 0), and the 95% confidence interval of the Y-intercept must contain the zero.  
With the combined data of Formulation I and II in both females and males, three subgroups could be 
distinguished which showed the gradual importance of plasma/liver hydrolysis in addition to tissue 
hydrolysis. When this is the case, both parent drug and intestinally formed metabolite are absorbed, 
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resulting in a measurable AUCt/kg of the metabolite when the AUCt/kg of ramipril is zero. Tang and 
Kalow first investigated the nature of carboxyesterases and reported the existence of three esterases in 
man, one in plasma and two different in the liver[27].  
Clinical Implications 
This study showed clearly that females showed a higher yield of active metabolite (AUCt/kg) than males, 
independent of the formulation. This difference after a fixed oral dose of 5 mg ramipril was caused by the 
lower body weight of the females. Fixed dose administration is common practice due to the available 
pharmaceutical formulations, while in the ideal situation the dose must be based on dose/kg or titrated to 
the required clinical effect. Both males and females showed three subgroups of subjects with high, 
medium, and low hydrolysis. The high metabolite yield can be attributed to plasma esterase plus hepatic 
microsomes and cytosol carboxyesterase activity. As a correlation between plasma concentration and 
enzyme activity of ACE inhibitory activity was demonstrated, the variation in plasma concentration 
indicates a probable variation in inhibitory activity and thus in effect[8,9]. The higher dose/kg in females 
may induce earlier the incidence of coughing than in males[28,29,30,31]. The effect may also vary due 
ACE gene polymorphism[24]. Ideally, the plasma concentration of ramipril and ramiprilat must be 
monitored and correlated with dose and clinical effect. When this is not feasible, the dose-clinical effect 
relationship should be titrated and monitored frequently when starting the therapy. 
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